US591431A
(en)
*
|
|
1897-10-12 |
|
Coupling for traps and pipes |
US458349A
(en)
*
|
|
1891-08-25 |
|
Hose-coupling |
US2806033A
(en)
|
1955-08-03 |
1957-09-10 |
Lewenstein |
Morphine derivative
|
DE1517480A1
(de)
|
1962-11-16 |
1969-05-22 |
Permutit Co Ltd |
Vorrichtung zum Regenerieren von Ionenaustauschern,insbesondere fuer die Wasserenthaertung
|
US3400197A
(en)
*
|
1965-01-26 |
1968-09-03 |
Robins Co Inc A H |
Compressible sustained release pharmaceutical tablet lipid-colloidal silica gel matrix fragment granules
|
US3456049A
(en)
*
|
1965-05-25 |
1969-07-15 |
Ciba Geigy Corp |
Gradual-release tablet
|
IL26896A
(en)
|
1966-01-19 |
1970-11-30 |
Endo Lab |
14 - Hydroxynormorphinins and 14 - Hydroxynormorphinones
|
US3558768A
(en)
*
|
1969-12-19 |
1971-01-26 |
Sterling Drug Inc |
Sustained release pharmaceutical compositions
|
US3879555A
(en)
*
|
1970-11-16 |
1975-04-22 |
Bristol Myers Co |
Method of treating drug addicts
|
US3845770A
(en)
|
1972-06-05 |
1974-11-05 |
Alza Corp |
Osmatic dispensing device for releasing beneficial agent
|
US3980766A
(en)
*
|
1973-08-13 |
1976-09-14 |
West Laboratories, Inc. |
Orally administered drug composition for therapy in the treatment of narcotic drug addiction
|
US3966940A
(en)
*
|
1973-11-09 |
1976-06-29 |
Bristol-Myers Company |
Analgetic compositions
|
DE2530563C2
(de)
*
|
1975-07-09 |
1986-07-24 |
Bayer Ag, 5090 Leverkusen |
Analgetische Arzneimittel mit vermindertem Mißbrauchspotential
|
US4140755A
(en)
*
|
1976-02-13 |
1979-02-20 |
Hoffmann-La Roche Inc. |
Sustained release tablet formulations
|
JPS5936110B2
(ja)
*
|
1976-11-01 |
1984-09-01 |
株式会社日立製作所 |
二重点火式点火装置
|
US4303691A
(en)
|
1977-11-09 |
1981-12-01 |
Anderson, Clayton & Co. |
Proteinaceous food product
|
NO793297L
(no)
|
1978-10-19 |
1980-04-22 |
Mallinckrodt Inc |
Fremgangsmaate til fremstilling av oksymorfon
|
US4309405A
(en)
*
|
1979-08-09 |
1982-01-05 |
American Home Products Corporation |
Sustained release pharmaceutical compositions
|
US4248858A
(en)
*
|
1979-08-09 |
1981-02-03 |
American Home Products Corporation |
Sustained release pharmaceutical compositions
|
US4252786A
(en)
*
|
1979-11-16 |
1981-02-24 |
E. R. Squibb & Sons, Inc. |
Controlled release tablet
|
US4457933A
(en)
*
|
1980-01-24 |
1984-07-03 |
Bristol-Myers Company |
Prevention of analgesic abuse
|
US4489080A
(en)
*
|
1981-06-26 |
1984-12-18 |
The Upjohn Company |
Process for analgesic treatment
|
US4366159A
(en)
*
|
1981-09-08 |
1982-12-28 |
Michael Richard Magruder |
Nalbuphine-narcotic analgesic composition and method of producing analgesia
|
US4415547A
(en)
*
|
1982-06-14 |
1983-11-15 |
Sterling Drug Inc. |
Sustained-release pharmaceutical tablet and process for preparation thereof
|
US4777174A
(en)
|
1982-07-22 |
1988-10-11 |
Analgesic Associates |
Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same
|
US4656177A
(en)
*
|
1982-07-22 |
1987-04-07 |
Analgesic Associates |
Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same
|
US4464376A
(en)
*
|
1982-07-22 |
1984-08-07 |
Richardson-Vicks, Inc. |
Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same
|
CA1217429A
(en)
|
1982-07-22 |
1987-02-03 |
Eugene M. Laska |
Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same
|
US4486436A
(en)
|
1982-07-22 |
1984-12-04 |
Analgesic Associates |
Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same
|
US4587249A
(en)
*
|
1982-07-22 |
1986-05-06 |
Analgesic Associates |
Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same
|
US4521402A
(en)
*
|
1983-01-03 |
1985-06-04 |
Verex Laboratories, Inc. |
Constant release rate solid oral dosage formulations of hydrazine
|
US4461759A
(en)
*
|
1983-01-03 |
1984-07-24 |
Verex Laboratories, Inc. |
Constant release rate solid oral dosage formulations of veropamil
|
US4522804A
(en)
*
|
1983-01-03 |
1985-06-11 |
Verex Laboratories, Inc. |
Constant release rate solid oral dosage formulations of propranolol
|
US4521401A
(en)
*
|
1983-01-03 |
1985-06-04 |
Verex Laboratories, Inc. |
Constant release rate solid oral dosage formulations of quinidine
|
US4567183A
(en)
|
1983-03-11 |
1986-01-28 |
Analgesic Associates |
Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same
|
US4479956A
(en)
|
1983-04-26 |
1984-10-30 |
Analgeic Associates |
Analgesic compositions comprising propiram and methods of using same
|
US4558051A
(en)
|
1983-10-11 |
1985-12-10 |
Richardson-Vicks, Inc. |
Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same
|
JPS60100516A
(ja)
|
1983-11-04 |
1985-06-04 |
Takeda Chem Ind Ltd |
徐放型マイクロカプセルの製造法
|
GB8332556D0
(en)
*
|
1983-12-06 |
1984-01-11 |
Reckitt & Colmann Prod Ltd |
Analgesic compositions
|
JPS6124516A
(ja)
*
|
1984-07-12 |
1986-02-03 |
Fujisawa Pharmaceut Co Ltd |
持続性錠剤
|
US4610870A
(en)
*
|
1984-10-05 |
1986-09-09 |
E. R. Squibb & Sons, Inc. |
Controlled release formulation
|
GB8430346D0
(en)
*
|
1984-11-30 |
1985-01-09 |
Reckitt & Colmann Prod Ltd |
Analgesic compositions
|
US4569937A
(en)
*
|
1985-02-11 |
1986-02-11 |
E. I. Du Pont De Nemours And Company |
Analgesic mixture of oxycodone and ibuprofen
|
US4599114A
(en)
*
|
1985-02-11 |
1986-07-08 |
Atkinson George K |
Treatment of titanium dioxide and other pigments to improve dispersibility
|
GB8514665D0
(en)
*
|
1985-06-11 |
1985-07-10 |
Eroceltique Sa |
Oral pharmaceutical composition
|
GB2176999B
(en)
|
1985-06-22 |
1989-07-12 |
Stanley Stewart Davis |
Sustained release medicament
|
GB8521350D0
(en)
*
|
1985-08-28 |
1985-10-02 |
Euro Celtique Sa |
Analgesic composition
|
GB8601204D0
(en)
*
|
1986-01-18 |
1986-02-19 |
Boots Co Plc |
Therapeutic agents
|
IE63321B1
(en)
*
|
1986-02-03 |
1995-04-05 |
Elan Corp Plc |
Drug delivery system
|
IT1191674B
(it)
*
|
1986-03-07 |
1988-03-23 |
Eurand Spa |
Formulazioni per la preparazione di farmaci a rilascio prolungato adatte alla somministrazione per via orale
|
SE8601624D0
(sv)
*
|
1986-04-11 |
1986-04-11 |
Haessle Ab |
New pharmaceutical preparations
|
US4795642A
(en)
|
1986-05-01 |
1989-01-03 |
Pharmacaps, Inc. |
Gelatin-encapsulated controlled-release composition
|
US4861598A
(en)
|
1986-07-18 |
1989-08-29 |
Euroceltique, S.A. |
Controlled release bases for pharmaceuticals
|
US4859461A
(en)
|
1986-07-30 |
1989-08-22 |
Fisons Corporation |
Coatable ion exchange resins
|
GB8626098D0
(en)
*
|
1986-10-31 |
1986-12-03 |
Euro Celtique Sa |
Controlled release hydromorphone composition
|
US4968508A
(en)
*
|
1987-02-27 |
1990-11-06 |
Eli Lilly And Company |
Sustained release matrix
|
GB8705083D0
(en)
*
|
1987-03-04 |
1987-04-08 |
Euro Celtique Sa |
Spheroids
|
FR2618073B1
(fr)
*
|
1987-07-16 |
1990-09-07 |
Pf Medicament |
Comprimes de type a matrice hydrophile a base de salbutamol et leur procede de preparation
|
US4792452A
(en)
*
|
1987-07-28 |
1988-12-20 |
E. R. Squibb & Sons, Inc. |
Controlled release formulation
|
US4994276A
(en)
*
|
1988-09-19 |
1991-02-19 |
Edward Mendell Co., Inc. |
Directly compressible sustained release excipient
|
SE8703881D0
(sv)
*
|
1987-10-08 |
1987-10-08 |
Haessle Ab |
New pharmaceutical preparation
|
GB8723896D0
(en)
*
|
1987-10-12 |
1987-11-18 |
Aps Research Ltd |
Controlled-release formulation
|
GB8728294D0
(en)
*
|
1987-12-03 |
1988-01-06 |
Reckitt & Colmann Prod Ltd |
Treatment compositions
|
US5096714A
(en)
*
|
1988-06-28 |
1992-03-17 |
Hauser-Kuhrts, Inc. |
Prolonged release drug tablet formulations
|
DE3822095A1
(de)
|
1988-06-30 |
1990-01-04 |
Klinge Co Chem Pharm Fab |
Neue arzneimittelformulierung sowie verfahren zu deren herstellung
|
GB8820353D0
(en)
*
|
1988-08-26 |
1988-09-28 |
Staniforth J N |
Controlled release tablet
|
US5128143A
(en)
*
|
1988-09-19 |
1992-07-07 |
Edward Mendell Co., Inc. |
Sustained release excipient and tablet formulation
|
US5169639A
(en)
|
1988-09-19 |
1992-12-08 |
Edward Mendell Co., Inc. |
Controlled release verapamil tablets
|
US5135757A
(en)
*
|
1988-09-19 |
1992-08-04 |
Edward Mendell Co., Inc. |
Compressible sustained release solid dosage forms
|
US5236714A
(en)
*
|
1988-11-01 |
1993-08-17 |
Alza Corporation |
Abusable substance dosage form having reduced abuse potential
|
US5202128A
(en)
*
|
1989-01-06 |
1993-04-13 |
F. H. Faulding & Co. Limited |
Sustained release pharmaceutical composition
|
GB8903328D0
(en)
*
|
1989-02-14 |
1989-04-05 |
Ethical Pharma Ltd |
Nifedipine-containing pharmaceutical compositions and process for the preparation thereof
|
US5126145A
(en)
*
|
1989-04-13 |
1992-06-30 |
Upsher Smith Laboratories Inc |
Controlled release tablet containing water soluble medicament
|
US4990535A
(en)
*
|
1989-05-03 |
1991-02-05 |
Schering Corporation |
Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
|
GB8926612D0
(en)
|
1989-11-24 |
1990-01-17 |
Erba Farmitalia |
Pharmaceutical compositions
|
US5126147A
(en)
*
|
1990-02-08 |
1992-06-30 |
Biosearch, Inc. |
Sustained release dosage form
|
JP2572673B2
(ja)
|
1990-07-25 |
1997-01-16 |
エスエス製薬株式会社 |
徐放性錠剤
|
SE9003903D0
(sv)
|
1990-12-07 |
1990-12-07 |
Astra Ab |
New pharmaceutical formulations
|
US5431922A
(en)
|
1991-03-05 |
1995-07-11 |
Bristol-Myers Squibb Company |
Method for administration of buspirone
|
US5286497A
(en)
|
1991-05-20 |
1994-02-15 |
Carderm Capital L.P. |
Diltiazem formulation
|
US5215758A
(en)
*
|
1991-09-11 |
1993-06-01 |
Euroceltique, S.A. |
Controlled release matrix suppository for pharmaceuticals
|
US5226331A
(en)
*
|
1991-10-03 |
1993-07-13 |
General Electric Company |
Apparatus and method for measuring the particle number rate and the velocity distribution of a sprayed stream
|
US5169638A
(en)
*
|
1991-10-23 |
1992-12-08 |
E. R. Squibb & Sons, Inc. |
Buoyant controlled release powder formulation
|
US5266331A
(en)
*
|
1991-11-27 |
1993-11-30 |
Euroceltique, S.A. |
Controlled release oxycodone compositions
|
US5958459A
(en)
|
1991-12-24 |
1999-09-28 |
Purdue Pharma L.P. |
Opioid formulations having extended controlled released
|
US5478577A
(en)
|
1993-11-23 |
1995-12-26 |
Euroceltique, S.A. |
Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
|
US5681585A
(en)
|
1991-12-24 |
1997-10-28 |
Euro-Celtique, S.A. |
Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
|
US5968551A
(en)
|
1991-12-24 |
1999-10-19 |
Purdue Pharma L.P. |
Orally administrable opioid formulations having extended duration of effect
|
US5580578A
(en)
|
1992-01-27 |
1996-12-03 |
Euro-Celtique, S.A. |
Controlled release formulations coated with aqueous dispersions of acrylic polymers
|
GB9202464D0
(en)
*
|
1992-02-05 |
1992-03-18 |
Danbiosyst Uk |
Composition for nasal administration
|
WO1993017673A1
(en)
|
1992-03-03 |
1993-09-16 |
Top Gold Pty., Limited |
Sustained release analgesics
|
DE4227385A1
(de)
|
1992-08-19 |
1994-02-24 |
Kali Chemie Pharma Gmbh |
Pankreatinmikropellets
|
US5512578A
(en)
*
|
1992-09-21 |
1996-04-30 |
Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University |
Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists
|
USRE36547E
(en)
|
1992-09-21 |
2000-02-01 |
Albert Einstein College Of Medicine Of Yeshiva University |
Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists
|
US5330761A
(en)
*
|
1993-01-29 |
1994-07-19 |
Edward Mendell Co. Inc. |
Bioadhesive tablet for non-systemic use products
|
IL110014A
(en)
*
|
1993-07-01 |
1999-11-30 |
Euro Celtique Sa |
Solid controlled-release oral dosage forms of opioid analgesics
|
US5773025A
(en)
|
1993-09-09 |
1998-06-30 |
Edward Mendell Co., Inc. |
Sustained release heterodisperse hydrogel systems--amorphous drugs
|
US5662933A
(en)
|
1993-09-09 |
1997-09-02 |
Edward Mendell Co., Inc. |
Controlled release formulation (albuterol)
|
US5455046A
(en)
|
1993-09-09 |
1995-10-03 |
Edward Mendell Co., Inc. |
Sustained release heterodisperse hydrogel systems for insoluble drugs
|
US5399358A
(en)
*
|
1993-11-12 |
1995-03-21 |
Edward Mendell Co., Inc. |
Sustained release formulations for 24 hour release of metroprolol
|
KR100354702B1
(ko)
|
1993-11-23 |
2002-12-28 |
유로-셀티크 소시에떼 아노뉨 |
약학조성물의제조방법및서방형조성물
|
GB9401894D0
(en)
|
1994-02-01 |
1994-03-30 |
Rhone Poulenc Rorer Ltd |
New compositions of matter
|
US5543434A
(en)
|
1994-02-25 |
1996-08-06 |
Weg; Stuart L. |
Nasal administration of ketamine to manage pain
|
US5399359A
(en)
|
1994-03-04 |
1995-03-21 |
Edward Mendell Co., Inc. |
Controlled release oxybutynin formulations
|
US5399362A
(en)
|
1994-04-25 |
1995-03-21 |
Edward Mendell Co., Inc. |
Once-a-day metoprolol oral dosage form
|
HU219818B
(hu)
|
1994-04-25 |
2001-08-28 |
Edward Mendell Co. Inc. |
Elnyújtott hatóanyag-leadású hordozóanyag
|
US5958458A
(en)
|
1994-06-15 |
1999-09-28 |
Dumex-Alpharma A/S |
Pharmaceutical multiple unit particulate formulation in the form of coated cores
|
US5633000A
(en)
*
|
1994-06-23 |
1997-05-27 |
Axxia Technologies |
Subcutaneous implant
|
US5914131A
(en)
|
1994-07-07 |
1999-06-22 |
Alza Corporation |
Hydromorphone therapy
|
US5556837A
(en)
|
1994-08-01 |
1996-09-17 |
Regeneron Pharmaceuticals Inc. |
Methods for treating addictive disorders
|
US5965161A
(en)
|
1994-11-04 |
1999-10-12 |
Euro-Celtique, S.A. |
Extruded multi-particulates
|
GB9426407D0
(en)
|
1994-12-30 |
1995-03-01 |
Sandoz Ltd |
Improvements in or relating to organic compounds
|
US5948438A
(en)
|
1995-01-09 |
1999-09-07 |
Edward Mendell Co., Inc. |
Pharmaceutical formulations having improved disintegration and/or absorptivity
|
FR2729857B1
(fr)
|
1995-01-27 |
1997-04-04 |
Rhone Poulenc Chimie |
Compositions pharmaceutiques sous forme de comprimes a liberation prolongee a base de granules en polysaccharides de haut poids moleculaire
|
US5686107A
(en)
|
1995-01-30 |
1997-11-11 |
Fmc Corporation |
Chewable pharmaceutical tablets
|
US5612053A
(en)
*
|
1995-04-07 |
1997-03-18 |
Edward Mendell Co., Inc. |
Controlled release insufflation carrier for medicaments
|
US5567754A
(en)
|
1995-08-23 |
1996-10-22 |
Kerr-Mcgee Corporation |
Pigments with improved dispersibility in thermoplastic resins
|
JPH11511466A
(ja)
|
1995-08-30 |
1999-10-05 |
スチュアート エル ウェグ |
苦痛を管理しおよび薬物依存性を軽減するための、ケタミンの投与
|
WO1997026865A1
(en)
|
1996-01-29 |
1997-07-31 |
Edward Mendell Co., Inc. |
Sustained release excipient
|
US6245351B1
(en)
|
1996-03-07 |
2001-06-12 |
Takeda Chemical Industries, Ltd. |
Controlled-release composition
|
JP3134187B2
(ja)
|
1996-03-07 |
2001-02-13 |
武田薬品工業株式会社 |
放出制御組成物
|
US6103258A
(en)
*
|
1996-04-12 |
2000-08-15 |
Simon; David Lew |
Salts and bases of the 17-(Cyclopropylmethyl)-4,5 alpha-epoxy-6-Methylenemorphinan-3,14 diol molecule for optimizing dopamine homeostasis during administration of opioid analgesics
|
CA2461157C
(en)
|
1996-04-18 |
2007-08-28 |
Penwest Pharmaceutical Co. |
Sustained release heterodisperse hydrogel systems - amorphous drugs
|
AU3581397A
(en)
|
1996-06-28 |
1998-01-21 |
Knoll Pharmaceutical Company |
Slow release pharmaceutical compositions and methods of making same
|
AU695734B2
(en)
*
|
1996-07-08 |
1998-08-20 |
Penwest Pharmaceuticals Co. |
Sustained release matrix for high-dose insoluble drugs
|
US6248789B1
(en)
*
|
1996-08-29 |
2001-06-19 |
Stuart L. Weg |
Administration of ketamine to manage pain and to reduce drug dependency
|
US5891474A
(en)
*
|
1997-01-29 |
1999-04-06 |
Poli Industria Chimica, S.P.A. |
Time-specific controlled release dosage formulations and method of preparing same
|
DE19710008A1
(de)
|
1997-03-12 |
1998-09-17 |
Basf Ag |
Feste, mindestens zweiphasige Zubereitungsformen eines Opioid-Analgeticums mit verzögerter Freisetzung
|
JP4083818B2
(ja)
*
|
1997-06-06 |
2008-04-30 |
ディポメド,インコーポレイティド |
高度可溶性薬物の制御された放出のための胃滞留性の経口薬物投与形
|
JP3739410B2
(ja)
|
1997-07-02 |
2006-01-25 |
ユーロ−セルティーク エス.エイ. |
安定化された徐放性トラマドール製剤
|
US6391336B1
(en)
*
|
1997-09-22 |
2002-05-21 |
Royer Biomedical, Inc. |
Inorganic-polymer complexes for the controlled release of compounds including medicinals
|
WO1999017763A1
(en)
|
1997-10-03 |
1999-04-15 |
The Governors Of The University Of Alberta |
Postsurgical treatment with dichloroacetate
|
US5904937A
(en)
|
1997-10-03 |
1999-05-18 |
Fmc Corporation |
Taste masked pharmaceutical compositions
|
US6056977A
(en)
|
1997-10-15 |
2000-05-02 |
Edward Mendell Co., Inc. |
Once-a-day controlled release sulfonylurea formulation
|
US6193991B1
(en)
*
|
1997-10-29 |
2001-02-27 |
Atul J. Shukla |
Biodegradable delivery systems of biologically active substances
|
US6102358A
(en)
*
|
1997-11-03 |
2000-08-15 |
Mcleary; Joseph Butler |
Counterpoise and mounting clamp for a musical drum
|
RS50070B
(sr)
*
|
1997-12-22 |
2009-01-22 |
Euro-Celtique S.A., |
Oralni dozni oblik sa kombinacijom opijatnog agonista i antagonista
|
US6375957B1
(en)
|
1997-12-22 |
2002-04-23 |
Euro-Celtique, S.A. |
Opioid agonist/opioid antagonist/acetaminophen combinations
|
EP1041988A4
(en)
|
1997-12-22 |
2002-03-13 |
Euro Celtique Sa |
METHOD FOR PREVENTING ABUSE OF OPIOID DOSES FORMS
|
US6245357B1
(en)
*
|
1998-03-06 |
2001-06-12 |
Alza Corporation |
Extended release dosage form
|
US6143325A
(en)
|
1998-06-05 |
2000-11-07 |
Bristol-Myers Squibb Company |
Nefazodone dosage form
|
KR20000011247A
(ko)
*
|
1998-07-23 |
2000-02-25 |
김윤 |
다당류를이용한대장선택성약물전달조성물및약학제제
|
GB9816723D0
(en)
|
1998-08-01 |
1998-09-30 |
Boots Co Plc |
Therapeutic agents
|
DE29818454U1
(de)
|
1998-10-15 |
1999-01-14 |
Euroceltique S.A., Luxemburg/Luxembourg |
Opioid-Analgetikum
|
US6806294B2
(en)
|
1998-10-15 |
2004-10-19 |
Euro-Celtique S.A. |
Opioid analgesic
|
PL205109B1
(pl)
|
1998-11-02 |
2010-03-31 |
Elan Pharma Int Ltd |
Wielocząstkowa kompozycja metylofenidatu o modyfikowanym uwalnianiu i jej zastosowanie
|
US6242001B1
(en)
|
1998-11-30 |
2001-06-05 |
Mcneil-Ppc, Inc. |
Method for producing dispersible sterol and stanol compounds
|
EP1005863A1
(en)
|
1998-12-04 |
2000-06-07 |
Synthelabo |
Controlled-release dosage forms comprising a short acting hypnotic or a salt thereof
|
FR2787715B1
(fr)
|
1998-12-23 |
2002-05-10 |
Synthelabo |
Composition pharmaceutique comprenant un compose hypnotique ou un de ses sels pharmaceutiquement acceptables
|
PE20001396A1
(es)
|
1999-01-18 |
2000-12-23 |
Gruenenthal Chemie |
Formulaciones medicamentosas retardadas que contienen una combinacion de un opioide o una sal fisiologicamente tolerables del mismo, un o-agonista
|
US6166211A
(en)
*
|
1999-03-19 |
2000-12-26 |
Endo Pharmaceuticals, Inc. |
Sequential benzylic oxidations of the naloxone ring system
|
US20030170181A1
(en)
|
1999-04-06 |
2003-09-11 |
Midha Kamal K. |
Method for preventing abuse of methylphenidate
|
US6306425B1
(en)
|
1999-04-09 |
2001-10-23 |
Southern Research Institute |
Injectable naltrexone microsphere compositions and their use in reducing consumption of heroin and alcohol
|
MXPA01010377A
(es)
|
1999-04-13 |
2002-10-23 |
Beecham Pharm Pte Ltd |
Metodo novedoso de tratamiento.
|
EP1064937A1
(en)
|
1999-06-28 |
2001-01-03 |
Sanofi-Synthelabo |
Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof
|
MXPA02000725A
(es)
|
1999-07-29 |
2003-07-14 |
Roxane Lab Inc |
Formulacion opioide de liberacion sostenida.
|
US20030118641A1
(en)
|
2000-07-27 |
2003-06-26 |
Roxane Laboratories, Inc. |
Abuse-resistant sustained-release opioid formulation
|
KR100345214B1
(ko)
|
1999-08-17 |
2002-07-25 |
이강춘 |
생체적합성 고분자가 수식된 펩타이드의 비점막 전달
|
DE60015370T2
(de)
|
1999-08-27 |
2006-03-09 |
Southern Research Institute, Birmingham |
Injizierbare buprenorphinhaltige mikrosphärenzusammensetzungen und ihre verwendung zur reduktion von heroin- und alkoholkonsum
|
US6436977B1
(en)
|
1999-09-29 |
2002-08-20 |
Pfizer Inc. |
Dosing regimens for lasofoxifene
|
WO2001022940A1
(en)
|
1999-09-30 |
2001-04-05 |
Edward Mendell Co., Inc. |
Sustained release matrix systems for highly soluble drugs
|
ATE526950T1
(de)
|
1999-10-29 |
2011-10-15 |
Euro Celtique Sa |
Hydrocodon-formulierungen mit gesteuerter freisetzung
|
JP4100910B2
(ja)
|
1999-12-23 |
2008-06-11 |
ファイザー・プロダクツ・インク |
ヒドロゲル駆動の薬物剤形
|
DE60115840T2
(de)
|
2000-01-19 |
2006-07-13 |
Mannkind Corp., Danbury |
Formulierung mit mehrfach gepulster wirkstofffreisetzung
|
US6716449B2
(en)
*
|
2000-02-08 |
2004-04-06 |
Euro-Celtique S.A. |
Controlled-release compositions containing opioid agonist and antagonist
|
EP2517710B1
(en)
*
|
2000-02-08 |
2015-03-25 |
Euro-Celtique S.A. |
Tamper-resistant oral opioid agonist formulations
|
CA2386794A1
(en)
|
2000-07-13 |
2002-01-24 |
Euro-Celtique, S.A. |
Salts and bases of 17-(cyclopropylmethyl)-4,5 alpha-epoxy-6-methylenemorphinan-3,14 diol for optimizing dopamine homeostasis during administration of opioid analgesics
|
US20020038310A1
(en)
|
2000-07-17 |
2002-03-28 |
Reitberg Donald P. |
Single-patient drug trials used with accumulated database: genomic markers
|
US6296842B1
(en)
|
2000-08-10 |
2001-10-02 |
Alkermes Controlled Therapeutics, Inc. |
Process for the preparation of polymer-based sustained release compositions
|
WO2002013886A2
(en)
|
2000-08-15 |
2002-02-21 |
University Of Kentucky Research Foundation |
Programmable multi-dose intranasal drug delivery device
|
KR20030059803A
(ko)
|
2000-10-03 |
2003-07-10 |
펜웨스트 파마슈티칼스 컴퍼니 |
다수의 약학적 활성 물질을 다양한 방출 속도로 전달하는시스템
|
US20020187192A1
(en)
|
2001-04-30 |
2002-12-12 |
Yatindra Joshi |
Pharmaceutical composition which reduces or eliminates drug abuse potential
|
AU2002303718B2
(en)
|
2001-05-11 |
2008-02-28 |
Endo Pharmaceuticals, Inc. |
Abuse-resistant opioid dosage form
|
CN1525851A
(zh)
|
2001-05-11 |
2004-09-01 |
������ҩ������˾ |
抗滥用阿片样物质控释剂型
|
AU2002339378A1
(en)
|
2001-05-22 |
2002-12-03 |
Euro-Celtique |
Compartmentalized dosage form
|
US20030064122A1
(en)
|
2001-05-23 |
2003-04-03 |
Endo Pharmaceuticals, Inc. |
Abuse resistant pharmaceutical composition containing capsaicin
|
US8329216B2
(en)
|
2001-07-06 |
2012-12-11 |
Endo Pharmaceuticals Inc. |
Oxymorphone controlled release formulations
|
ATE376832T1
(de)
|
2001-07-06 |
2007-11-15 |
Penwest Pharmaceuticals Co |
Verzögert freisetzende formulierungen von oxymorphon
|
CA2452871C
(en)
|
2001-07-06 |
2011-10-04 |
Endo Pharmaceuticals, Inc. |
Oxymorphone controlled release formulations
|
ATE419039T1
(de)
|
2001-07-18 |
2009-01-15 |
Euro Celtique Sa |
Pharmazeutische kombinationen von oxycodon und naloxon
|
AU2002321879A1
(en)
|
2001-08-06 |
2003-03-03 |
Thomas Gruber |
Pharmaceutical formulation containing dye
|
US20030044458A1
(en)
|
2001-08-06 |
2003-03-06 |
Curtis Wright |
Oral dosage form comprising a therapeutic agent and an adverse-effect agent
|
US20030157168A1
(en)
|
2001-08-06 |
2003-08-21 |
Christopher Breder |
Sequestered antagonist formulations
|
US7332182B2
(en)
|
2001-08-06 |
2008-02-19 |
Purdue Pharma L.P. |
Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
|
DE60232417D1
(de)
|
2001-08-06 |
2009-07-02 |
Euro Celtique Sa |
Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist
|
EP1414418A1
(en)
|
2001-08-06 |
2004-05-06 |
Euro-Celtique S.A. |
Compositions and methods to prevent abuse of opioids
|
US7157103B2
(en)
|
2001-08-06 |
2007-01-02 |
Euro-Celtique S.A. |
Pharmaceutical formulation containing irritant
|
US7141250B2
(en)
|
2001-08-06 |
2006-11-28 |
Euro-Celtique S.A. |
Pharmaceutical formulation containing bittering agent
|
US7144587B2
(en)
|
2001-08-06 |
2006-12-05 |
Euro-Celtique S.A. |
Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent
|
US20030068375A1
(en)
|
2001-08-06 |
2003-04-10 |
Curtis Wright |
Pharmaceutical formulation containing gelling agent
|
US7842307B2
(en)
|
2001-08-06 |
2010-11-30 |
Purdue Pharma L.P. |
Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
|
CA2455420A1
(en)
|
2001-08-06 |
2003-02-20 |
Euro-Celtique, S.A. |
Compositions and methods to prevent abuse of opioids
|
US20030049272A1
(en)
|
2001-08-30 |
2003-03-13 |
Yatindra Joshi |
Pharmaceutical composition which produces irritation
|
US20030059397A1
(en)
|
2001-09-17 |
2003-03-27 |
Lyn Hughes |
Dosage forms
|
US20030068276A1
(en)
|
2001-09-17 |
2003-04-10 |
Lyn Hughes |
Dosage forms
|
US20030091635A1
(en)
|
2001-09-26 |
2003-05-15 |
Baichwal Anand R. |
Opioid formulations having reduced potential for abuse
|
EP1450824A4
(en)
|
2001-11-02 |
2005-09-28 |
Elan Corp Plc |
PHARMACEUTICAL COMPOSITION
|
US20030158264A1
(en)
|
2002-02-20 |
2003-08-21 |
Ramachandran Radhakrishnan |
Orally administrable pharmaceutical formulation comprising ephedrine hydrochloride and process for preparing the same
|
US20050203098A1
(en)
|
2002-02-27 |
2005-09-15 |
Alain Moussy |
Use of tyrosine kinase inhibitors for treating substance use disorders
|
EP1578350B1
(en)
|
2002-03-26 |
2009-05-27 |
Euro-Celtique S.A. |
Sustained-release gel coated compositions
|
US7524515B2
(en)
|
2003-01-10 |
2009-04-28 |
Mutual Pharmaceuticals, Inc. |
Pharmaceutical safety dosage forms
|
US9512125B2
(en)
|
2004-11-19 |
2016-12-06 |
The Regents Of The University Of California |
Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
|
US20060193911A1
(en)
|
2005-02-28 |
2006-08-31 |
Penwest Pharmaceuticals Co., |
Controlled release venlafaxine formulations
|
CA2617164A1
(en)
|
2005-08-01 |
2007-02-08 |
Alpharma Inc. |
Alcohol resistant pharmaceutical formulations
|
DK2402005T3
(da)
|
2005-08-24 |
2021-03-15 |
Endo Pharmaceuticals Inc |
Formuleringer med langvarig frigivelse af nalbuphin
|
PL116330U1
(en)
|
2005-10-31 |
2007-04-02 |
Alza Corp |
Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
|
WO2007078895A2
(en)
|
2005-12-30 |
2007-07-12 |
Biovail Laboratories International S.R.L. |
Modified release formulations of tramadol and uses thereof
|
US20070212414A1
(en)
|
2006-03-08 |
2007-09-13 |
Penwest Pharmaceuticals Co. |
Ethanol-resistant sustained release formulations
|
US20080119501A1
(en)
|
2006-04-28 |
2008-05-22 |
Hein William A |
Immediate release oxymorphone compositions and methods of using same
|
JP2010505948A
(ja)
|
2006-10-10 |
2010-02-25 |
ペンウェスト ファーマシューティカルズ カンパニー |
オキシモルフォンのロバスト性持続放出製剤およびその使用方法
|
US20080085303A1
(en)
|
2006-10-10 |
2008-04-10 |
Penwest Pharmaceuticals Co. |
Robust sustained release formulations of oxymorphone and methods of use thereof
|
US20080085304A1
(en)
|
2006-10-10 |
2008-04-10 |
Penwest Pharmaceuticals Co. |
Robust sustained release formulations
|
US20080085305A1
(en)
|
2006-10-10 |
2008-04-10 |
Penwest Pharmaceuticals Co. |
Robust sustained release formulations of oxymorphone
|
CN101578095A
(zh)
|
2006-10-10 |
2009-11-11 |
潘威斯脱药物公司 |
稳健的缓释制剂
|
EP2079453A1
(en)
|
2006-10-10 |
2009-07-22 |
Penwest Pharmaceuticals Co. |
Robust sustained release formulations
|
US20080318993A1
(en)
|
2007-06-21 |
2008-12-25 |
Endo Pharmaceuticals, Inc. |
Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Hepatic Impairment
|
US20080318994A1
(en)
|
2007-06-21 |
2008-12-25 |
Endo Pharmaceuticals, Inc. |
Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Renal Impairment
|